Healthcare / BiotechnologyNasdaqCM
$2.10
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF n/d · quality 50.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
5/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$138M
P/E
N/A
•EV/EBITDA
N/A
•ROE
24.1%
↑Gross Margin
N/A
•Debt/Equity
N/A
•Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2010–2025 · 15 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
—
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-30.8M · FCF —
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||
| Net Income | $-30.8M | $-30.8M | $-47.0M | $-41.1M | $-38.8M | $-30.5M | $-23.5M | $-13.3M | $-13.9M | $-16.2M | $-21.4M | $-20.0M | $-15.8M | $-12.1M | $-9.7M | $-10.9M | $-5.6M |
| EBITDA | — | — | $-42.4M | $-38.1M | $-38.4M | $-30.2M | $-23.4M | $-13.4M | $-13.6M | $-16.2M | $-21.5M | $-20.1M | $-15.4M | $-12.1M | $-9.9M | $-10.4M | $-4.9M |
| EPS | -0.48 | -0.48 | -0.76 | -0.74 | -0.65 | -0.52 | -0.41 | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||||
| Free Cash Flow | — | — | — | — | — | — | — | — | — | — | — | — | — | $-66.0M | $-7.5M | $-5.7M | — |
| Returns | |||||||||||||||||
| ROE | 24.1% | 24.1% | 44.9% | 66.3% | 114.3% | -3418.5% | -104.4% | -30.3% | -268.6% | 3063.2% | -208.3% | -111.0% | -74.5% | -816.2% | -830.5% | 513.6% | 332.3% |
| Growth & Yield | |||||||||||||||||
| EPS Growth | 36.8% | 36.8% | -2.7% | -13.8% | -25.0% | -26.8% | — | — | — | — | — | — | — | — | — | — | — |
Returns (%)
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.